Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553909 | 1.00 | ALDH1A1 (0.56) | ALDH1A1RAB9ANPC1GRM5GRM4 | |
| SCHEMBL4712658 | 0.83 | RAB9A (0.76) | ALDH1A1RAB9ANPC1GRM5GRM4 | |
| SCHEMBL710474 | 0.81 | RAB9A (0.58) | ALDH1A1RAB9ANPC1GRM5GRM4 | |
| SCHEMBL710475 | 0.81 | RAB9A (0.58) | ALDH1A1RAB9ANPC1GRM5GRM4 | |
| SCHEMBL9797858 | 0.80 | RAB9A (0.56) | ALDH1A1RAB9ANPC1GRM5GRM4 | |
| SCHEMBL9797862 | 0.80 | RAB9A (0.56) | ALDH1A1RAB9ANPC1GRM5GRM4 | |
| SCHEMBL230251 | 0.79 | — | — | |
| SCHEMBL29951696 | 0.79 | — | — | |
| SCHEMBL20083328 | 0.77 | ALDH1A1 (0.53) | ALDH1A1RAB9ANPC1GRM5GRM4 | |
| SCHEMBL28279453 | 0.77 | ALDH1A1 (0.52) | ALDH1A1RAB9ANPC1GRM5GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023193760-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2023-10-12 | — | — | WO | disclosed |
| EP-2558465-B1 | TRICYCLIC PYRIDYL-VINYL-PYROLES AS PAR1 INHIBITORS | SANOFI SA (FR) | 2014-12-17 | — | — | EP | disclosed |
| US-8871798-B2 | Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors | SANOFI (FR) | 2014-10-28 | — | — | US | disclosed |
| EP-2558462-B1 | Pyridyl-vinyl-pyrazolo-chinolines as PAR1 inhibitors | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-8791133-B2 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| EP-2558465-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-20 | — | — | EP | disclosed |
| EP-2558462-A1 | PYRIDYL-VINYL PYRAZOLOQUINOLINES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-20 | — | — | EP | disclosed |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| WO-2011128420-A1 | PYRIDYL-VINYL PYRAZOLOQUINOLINES AS PAR1 INHIBITORS | SANOFI (FR) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128421-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | F2R, F2RL1, F2RL3 | ALDH1A1 1434/4885RAB9A 2276/4885NPC1 2227/4885 |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | F2R, F2RL1, F2RL3 | ALDH1A1 1775/4885RAB9A 2325/4885NPC1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.